KR102252926B1 - 항정신병약물 유발성 체중 증가에 대한 유전자 마커 및 그의 사용 방법 - Google Patents

항정신병약물 유발성 체중 증가에 대한 유전자 마커 및 그의 사용 방법 Download PDF

Info

Publication number
KR102252926B1
KR102252926B1 KR1020167012720A KR20167012720A KR102252926B1 KR 102252926 B1 KR102252926 B1 KR 102252926B1 KR 1020167012720 A KR1020167012720 A KR 1020167012720A KR 20167012720 A KR20167012720 A KR 20167012720A KR 102252926 B1 KR102252926 B1 KR 102252926B1
Authority
KR
South Korea
Prior art keywords
subject
seq
schizophrenia
weight gain
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167012720A
Other languages
English (en)
Korean (ko)
Other versions
KR20160098188A (ko
Inventor
클레멘트 씨. 자이
제임스 엘. 케네디
다니엘 제이. 뮬러
Original Assignee
센터 포 어딕션 앤드 멘탈 헬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센터 포 어딕션 앤드 멘탈 헬스 filed Critical 센터 포 어딕션 앤드 멘탈 헬스
Publication of KR20160098188A publication Critical patent/KR20160098188A/ko
Application granted granted Critical
Publication of KR102252926B1 publication Critical patent/KR102252926B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167012720A 2013-10-17 2014-10-17 항정신병약물 유발성 체중 증가에 대한 유전자 마커 및 그의 사용 방법 Expired - Fee Related KR102252926B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892094P 2013-10-17 2013-10-17
US61/892,094 2013-10-17
PCT/CA2014/051000 WO2015054792A1 (en) 2013-10-17 2014-10-17 Genetic markers for antipsychotic induced weight gain and methods for use thereof

Publications (2)

Publication Number Publication Date
KR20160098188A KR20160098188A (ko) 2016-08-18
KR102252926B1 true KR102252926B1 (ko) 2021-05-20

Family

ID=52827506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167012720A Expired - Fee Related KR102252926B1 (ko) 2013-10-17 2014-10-17 항정신병약물 유발성 체중 증가에 대한 유전자 마커 및 그의 사용 방법

Country Status (12)

Country Link
US (1) US10301678B2 (enExample)
EP (2) EP3561076A1 (enExample)
JP (1) JP6524073B2 (enExample)
KR (1) KR102252926B1 (enExample)
CN (1) CN106029901A (enExample)
AU (1) AU2014336928B2 (enExample)
CA (1) CA2943951C (enExample)
ES (1) ES2728072T3 (enExample)
IL (1) IL245159B (enExample)
PT (1) PT3058106T (enExample)
SG (1) SG11201602998QA (enExample)
WO (1) WO2015054792A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016085A2 (pt) * 2018-02-09 2020-12-15 Metabolomic Diagnostics Limited Métodos de previsão de nascimento prematuro a partir de pré-eclâmpsia usando biomarcadores metabólicos e proteicos
CN110317868B (zh) * 2019-08-09 2020-05-19 新疆医科大学第二附属医院 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039234A2 (en) 2001-11-06 2003-05-15 David Pickar Pharmacogenomics-based system for clinical applications
WO2013088135A1 (en) 2011-12-14 2013-06-20 Astrazeneca Ab Gabr-a2 diagnostic

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
PT728218E (pt) 1993-11-12 2008-04-08 Phri Properties Inc Sondas de hibridação para detecção de ácidos nucleicos, troncos universais, métodos e estojos
US8012718B2 (en) 2006-03-31 2011-09-06 Genomas, Inc. Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs
US20070292962A1 (en) * 2006-04-10 2007-12-20 Duke University Methods and compositions for genetic markers for autism
US7795033B2 (en) 2007-03-19 2010-09-14 The United States Of America As Represented By The Department Of Health And Human Services Methods to predict the outcome of treatment with antidepressant medication
US8476012B2 (en) 2008-04-18 2013-07-02 Genomas, Inc. Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039234A2 (en) 2001-11-06 2003-05-15 David Pickar Pharmacogenomics-based system for clinical applications
WO2013088135A1 (en) 2011-12-14 2013-06-20 Astrazeneca Ab Gabr-a2 diagnostic

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Genes, Brain and Behavior (2013) 12:525-531
Journal of Clinical Psychopharmacology (2015) 35(1):7-12
The American Journal of Human Genetics (2004) 74:705-714
The American Journal on Addictions (2012) 21(5):404-410

Also Published As

Publication number Publication date
US10301678B2 (en) 2019-05-28
CA2943951C (en) 2022-05-31
IL245159B (en) 2020-10-29
EP3561076A1 (en) 2019-10-30
CN106029901A (zh) 2016-10-12
SG11201602998QA (en) 2016-05-30
CA2943951A1 (en) 2015-04-23
ES2728072T3 (es) 2019-10-22
US20160237499A1 (en) 2016-08-18
IL245159A0 (en) 2016-06-30
EP3058106A4 (en) 2017-06-07
EP3058106B1 (en) 2019-02-27
WO2015054792A1 (en) 2015-04-23
JP6524073B2 (ja) 2019-06-05
JP2016534715A (ja) 2016-11-10
AU2014336928B2 (en) 2020-07-16
EP3058106A1 (en) 2016-08-24
PT3058106T (pt) 2019-05-30
KR20160098188A (ko) 2016-08-18

Similar Documents

Publication Publication Date Title
Hu et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder
Volpi et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia
Morris et al. No evidence for association of the dysbindin gene [DTNBP1] with schizophrenia in an Irish population-based study
Aulchenko et al. LPIN2 is associated with type 2 diabetes, glucose metabolism, and body composition
CN112424381A (zh) 包括arhgap32基因单碱基多态性的脑动脉瘤诊断用snp标志物
KR20160111925A (ko) 자살 위험과 연관된 유전적 마커 및 그의 사용 방법
JP2006518206A (ja) 処置中の自殺傾向を予測するための方法
KR102252926B1 (ko) 항정신병약물 유발성 체중 증가에 대한 유전자 마커 및 그의 사용 방법
KR102033813B1 (ko) 항정신병약물-베이스 치료에 의하여 유발된 추체외로 증상 (eps)의 개시를 예측하는 방법
CN113166810A (zh) 包括gba基因单碱基多态性的脑动脉瘤诊断用snp标志物
JP2008524999A (ja) 精神障害を治療するための組成物及び方法
US9752195B2 (en) TTC8 as prognostic gene for progressive retinal atrophy in dogs
AU2014336928A1 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
CA2664366C (en) Slc1a1 antipsychotic drug response markers
CN1973051A (zh) 用于预测对氯氮平治疗的应答性的生物标记
Claes et al. Human genetics of schizophrenia
JP7088519B2 (ja) 側弯症の検査方法
Sansom The prevalence of eight single nucleotide variations in overweight and obese participants
Barr et al. XIII World Congress on Psychiatric Genetics 2005 Sponsored by
HK1224705A1 (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
HK1224705B (en) Genetic markers for antipsychotic induced weight gain and methods for use thereof
Al-Saud The genetics of obesity in Saudi Arabian population
KR20070022710A (ko) 클로자핀 치료에 대한 반응성을 예측하기 위한 바이오마커
JP2011239697A (ja) パーキンソン病発症リスクマーカー
CA2517218A1 (en) Marker for psychosis or mood disorder

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240512

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240512